Trend
DailyDowntrend (confirmed)
4 hourSymmetric Triangle
1 hourLeaning Bullish
15 minLeaning Bullish
5 minConsolidating
Daily trend turns up above $5.51
Key levels
Resistance$5.15
Resistance$4.94
Support$4.72
Support$4.50
Latest news & SEC filings
NewsChampions Oncology earns recognition from BioTech Breakthrough
SEC FilingChampions Oncology, Inc. filed an insider trading report (Form 4)
All CSBR news →Champions Oncology is a research organization that provides preclinical and clinical oncology services to pharmaceutical and biotechnology companies. It maintains a large bank of patient-derived tumor models and offers in vivo, ex vivo, and computational studies to evaluate experimental cancer drugs. The company also licenses its tumor model data and sells a bioinformatics software platform on a subscription basis. It operates in North America, Europe, and Asia and is also pursuing its own oncology drug discovery programs.
Based on the company's 10-K filed Jul 27, 2026.
Nasdaq · Healthcare
SEPT Low Target
$0.00
SEPT Mid Target
$0.00
SEPT High Target
$0.00
Analyst Consensus
$0.00
Thesis
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for CSBR.
Start Free Trial →Valuation Verdict
OVERVALUED
Methods Used
P/E Forward, P/B
Fair Value
$1.91
10
Moat Score
NONE
4/9
Piotroski Score
-0.4
Altman Z-Score
Insider Signal
NEUTRAL
0 buys / 0 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
UNCHANGED
Short Squeeze Risk
LOW
Signal: NEUTRAL
| Name | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| ACKERMAN JOEL | director | Buy | 69,794 | $112K | Oct 15, 2026 |
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →Revenue YoY
4.4%
3yr Revenue CAGR
N/A%
EPS Growth YoY
-124.24%
FCF Growth YoY
-172.0%
Revenue Trend
STABLE
SEPT Investing tracks real-time dark pool institutional trades for CSBR, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 18:53:51 | $4.81 | 2,916 | $$14K | SELL |
| 16:18:31 | $4.77 | 1,000 | $$5K | SELL |
| 16:18:14 | $4.79 | 1,000 | $$5K | BUY |
| 14:50:55 | $4.82 | 1,731 | $$8K | BUY |
| 14:50:34 | $4.83 | 2,000 | $$10K | BUY |
5 dark pool trades shown · $$42K preview volume
Real-time institutional flow, block trades, and net positioning
SEPT's Trading AI has generated a free, downloadable PDF research report for CHAMPIONS ONCOLOGY, INC. (CSBR) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (1 articles analyzed), and SEC filing intelligence...
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →CHAMPIONS ONCOLOGY, INC. (CSBR) is at $4.82, up 1.47% (+$0.07) at the Nov 11, 2026 close.
Latest CSBR news — Nov 10, 2026: Champions Oncology earns recognition from BioTech Breakthrough · Nov 9, 2026: Champions Oncology, Inc. filed an insider trading report (Form 4)
CSBR last reported on Sep 10, 2026: EPS $0.05 vs -$0.01 expected — a beat of 600.0%.
CSBR does not currently pay a dividend.
Support: $4.72, $4.50, $4.30. Resistance: $4.94, $5.15, $5.39.
Insider activity: NEUTRAL, 0 buys and 0 sells in the last 90 days.
Nov 10, 2026: Champions Oncology earns recognition from BioTech Breakthrough · Nov 9, 2026: Champions Oncology, Inc. filed an insider trading report (Form 4)